Merck KGaA (Germany) has launched its new consumer brand Vivera in Latin America, and announced the transition of three additional brands from its Biopharma portfolio to its Consumer Health business in Latin America. The brands involved in the transfer are Anemidox, Confer, a drug for the treatment and prevention of iron deficiency-related anaemia at every stage of life, and Hepabionta, a liver protector. According to Merck KGaA, the transfer of these three brands begins from January 2016 onwards in Colombia, Ecuador, and Peru, and then 2017 in Chile.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
154.2 EUR | +0.59% | +1.08% | +7.04% |
Jul. 10 | Merck KGaA: share price down, analyst lowers target | CF |
Jul. 10 | MERCK KGAA : UBS lowers price target | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.04% | 73.13B | |
+31.10% | 10.38B | |
+37.94% | 5.16B | |
-17.33% | 4.73B | |
+21.49% | 3.81B | |
+24.92% | 2.26B | |
-36.84% | 1.88B | |
-43.31% | 1.77B | |
-0.50% | 1.64B | |
-1.11% | 1.57B |
- Stock Market
- Equities
- MRK Stock
- News Merck KGaA
- Merck KGaA Launches its New Consumer Brand Vivera in Latin America